Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis

Abstract Background Dipeptidyl peptidase 4 (DPP4) is a serine exopeptidase able to inactivate various oligopeptides, and also hepatokine. Hepatocyte-specific overexpression of DPP4 associated with hepatic insulin resistance liver steatosis. Method We examined whether weekly inhibitor omarigliptin (OMG) can improve function as well levels inflammation in type 2 diabetic patients non-alcoholic fatty disease (NAFLD). Further, we investigated the effects OMG patient biopsy-confirmed nonalcoholic steatohepatitis (NASH). Results In NAFLD patients, significantly decreased aminotransferase, aspartate gamma-glutamyl transpeptidase, homeostatic model assessment (HOMA-IR), high-sensitivity C-reactive protein (hsCRP), while no significant change was seen hemoglobin A1c or body mass index. NASH patient, improved markedly, fibrosis marker FIB-4 parallel HOMA-IR hsCRP. Slight but clear improvements intrahepatic fat deposition appeared be on diagnostic ultrasonography. Conclusion Weekly administration ameliorating may cause beneficial NAFLD/NASH.